Workflow
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
RAREUltragenyx Pharmaceutical(RARE) ZACKS·2025-02-13 23:11

Core Viewpoint - Ultragenyx reported a quarterly loss of 1.39pershare,whichwasworsethantheZacksConsensusEstimateofalossof1.39 per share, which was worse than the Zacks Consensus Estimate of a loss of 1.24, but an improvement from a loss of 1.52pershareayearago[1]FinancialPerformance−Thecompanypostedrevenuesof1.52 per share a year ago [1] Financial Performance - The company posted revenues of 164.88 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 1.01% and showing an increase from 127.39millionyear−over−year[2]−Overthelastfourquarters,UltragenyxhassurpassedconsensusEPSestimatestwotimesandtoppedconsensusrevenueestimatesthreetimes[2]StockPerformance−Ultragenyxshareshaveincreasedapproximately3.2127.39 million year-over-year [2] - Over the last four quarters, Ultragenyx has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Ultragenyx shares have increased approximately 3.2% since the beginning of the year, compared to a 2.9% gain in the S&P 500 [3] Future Outlook - The company's earnings outlook will be crucial for determining future stock performance, with current consensus EPS estimates at -1.36 for the coming quarter and -$4.98 for the current fiscal year [4][7] - The estimate revisions trend for Ultragenyx is currently mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Ultragenyx belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]